Phase II and Phase III Clinical Trials

• CT137 · PDF QOL outcomes in Bria-ABC late stage metastatic phase 3 trial Saranya Chumsri, Chaitali Nangia, Adriana Kahn, Lawrence Negret, Carmen Calfa, Blaise Bayer, Giuseppe Del Priore, Tamar Aghajanian, William Williams, Kelly McCann
• CT138 · PDF Preliminary delayed-type-hypersensitivity immune response results from open-label arm of on-going Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01 Snehal S. Patel, Jaye Thompson, F. Joseph Daugherty, Francois-Clement Bidard, William J. Gradishar, Marcus Schmidt, Miguel Martin, Joyce A. O’Shaughnessy, Hope S. Rugo, Cesar A. Santa-Maria, Laura M. Spring, Mothaffar F. Rimawi
• CT139 · PDF Germline HFE mutations predict for durable response to arginine depletion with pegargiminase-based chemotherapy in pleural mesothelioma Peter Wojciech Szlosarek, George Field, Iuliia Pavlyk, Matthew Young, Michael Allen, Josephine Carpentier, Riyaz Shah, Nick Maskell, David Houghton, Amanda Johnston, John Bomalaski, Louise Jones, Michael Sheaff
• CT140 · PDF Final Results from S2302-PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC) Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Maya Khalil, Brian S. Henick, James Moon, Pasarlai Ahmadzai, Michael LeBlanc, Daniel R. Carrizosa, Paul J. Hesketh, Ellen V. Sigal, Jeff Allen, Andreas N. Saltos, Bryan A. Faller, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray
• CT142 · PDF Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibody Michael J. Overman, Harshabad Singh, Alexander I. Spira, Jason T. Henry, Dani Castillo, Nataliya Uboha, Naomi Fei, Nicholas DeVito, Diana Hanna, Grace H. McGregor, Hui Zou, Minghan Wang, Satya (Nanu) Das, Rita Laeufle, Anwaar Saeed
• CT143 · PDF Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept study Harshabad Singh, Michael J. Overman, Alexander I. Spira, Jason T. Henry, Dani Castillo, Nataliya Uboha, Naomi Fei, Nicholas DeVito, Diana Hanna, Michael J. Chisamore, Grace H. McGregor, Hui Zou, Minghan Wang, Satya (Nanu) Das, Rita Laeufle, Anwaar Saeed
• CT144 · PDF Pharmacokinetics of spevatamig (PT886), a bispecific antibody targeting CLDN18.2 and CD47, in patients with advanced gastrointestinal cancers as monotherapy or combination therapy Anwaar Saeed, Harshabad Singh, Alexander I. Spira, Jason T. Henry, Dani Castillo, Nataliya Uboha, Naomi Fei, Nicholas DeVito, Diana Hanna, Grace H. McGregor, Hui Zou, Minghan Wang, Satya (Nanu) Das, Rita Laeufle, Michael J. Overman
• CT145 · PDF A phase II, multicenter, open-label study (COMPASSION-26) of cadonilimab, a PD-1/CTLA-4 bispecific antibody,combined with chemotherapy (chemo) as first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC) Wenming Wu, Xiafei Hong, Qi Xu, Gang Jin, Zhihua Li, He Tian, Heshui Wu, Yiping Mou, Baocai Xing, Dianrong Xiu, Zhifang Yao, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia
• CT146 · PDF Sequential treatment with surufatinib combined with gemcitabine and nab-paclitaxel (AG) or AG alone as first-line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC) after 6 weeks of AG induction therapy: A two-cohort, exploratory phase II study Jialin Li, Miaoyan Wei, Nan Du, Si Shi, Jin Xu, XianJun Yu
• CT147 · PDF High dose intravenous ascorbate with chemotherapy as NAC for muscle invasive cisplatin ineligible bladder cancer patients Qi Chen, John Taylor, Rahul Parikh, Ben Woolbright, Jeanne Drisko
• CT148 · PDF Safety, dosimetry, and RP2D determination of Ga‑68‑NGUL and Lu‑177‑DGUL (pocuvotide satetraxetan) in mCRPC: Results from a phase 1/2 study Seung-hwan Jeong, Cheol Kwak, Chang Wook Jeong, Sung Kyu Hong, Jae Lyun Lee, Eu Chang Hwang, Kyo Chul Koo, Keon Wook Kang, Gi Jeong Cheon, Minseok Suh
• CT149 · PDF A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis Justine Panian, Lin Liu, Minya Pu, Emily Pittman, Samuel Pena, Archana Ajmera, Yu-Wei Chen, Christos Kyriakopoulos, Qian Qin, James Michael Randall, Tian Zhang, Joshua Michael Lang, Akash Patnaik, Rana R. McKay
• CT150 Sintilimab plus cisplatin and nab-paclitaxel induction treatment for locally advanced borderline resectable esophageal squamous cell carcinoma: A single-arm, prospective, phase 2 study (NEOCRTEC2001) Xin Zhang, Jiadi Wu, Deshen Wang, Zhiqiang Wang, Qiaoqiao Li, Chao Ren, Yuhong Li, Hong Yang
• CT151 · PDF CDK4/6 inhibitor dalpiciclib combined with mFOLFOX6 in pretreated metastatic colorectal cancer: Results from a Simon two-stage phase II study Xiaoyu Xie, Zhaoliang Yu, Ziqin Lin, Weiwei Li, Dianke Chen, Xiaohui Zhai, Yufeng Chen, Xiaojian Wu
• CT152 · PDF Preliminary results from a phase II trial evaluating the safety and efficacy of JS207, a bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in patients with metastatic colorectal cancer Yong Gao, Zhiwei Li, Jianwei Yang, Shuqing Jin, Yiyi Yu, Chang Wang, Xiwen Huang, Jingdong Zhang, Yanhong Gu, Shuqin Ni, Yanlai Sun, Shirong Cai, Liang Han, Xinjun Liang, Haichuan Su, Chenxi Wang, Zhenyu Xu, Jing Xu, Chengbo Jia, Jianjun Zou, Lin Shen
• CT153 · PDF Feasibility of pegulicianine fluorescence guided surgery for detection of peritoneal surface malignancies Brian Schlossberg, Julia Kloetzl, Kate Smith, Jorge Ferrer, Jonathan Greer
• CT154 · PDF Clinical activity and safety of novel BRAF inhibitor plixorafenib (FORE8394) in BRAF V600-mutated advanced colorectal cancers (CRC) Rona Yaeger, Sunil Sharma, Aparna Parikh, Stacie Peacock Shepherd, Manish Monga, Ping Jiang, Jessica Jang, Michael Paz, Frank Tsai, Ulka Vaishampayan, Jordi Rodon
• CT155 · PDF Phase 1b trial of NG-350A, a CD40 agonist antibody expressing adenoviral vector, in combination with chemoradiotherapy (CRT), in patients with mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC): Initial results from the FORTRESS study Eric D. Miller, Pannaga Malalur, Sonal S. Noticewala, Arvind Dasari, Sheela Rao, Andry Santoso, Maria Hawkins, Douglas Brand, Rui Ru Ji, Korinna Pilz, Oliver Rosen
• CT156 · PDF ST316, a first in class beta-catenin antagonist, demonstrates safety and efficacy in metastatic colorectal cancer (mCRC) Anthony El-Khoueiry, Susanna V. Ulahannan, Steven Powell, Jason T. Henry, E. Gabriela Chiorean, Niharika Mettu, Zachary F. Mattes, Claudio Scuoppo, Joyce Gakuria, Franco Abbate, Jim A. Rotolo, Abi Vainstein-Haras
• CT157 · PDF MEDOCC-CrEATE trial update: Feasibility of measuring circulating tumor DNA post-surgery to guide adjuvant chemotherapy in stage II colon cancer patients Ingrid A. Franken, Suzanna J. Schraa, Steven L. C. Ketelaars, Carmen Rubio-Alarcón, Teunise Bisschop-Snetselaar, Bregje Adriaans, Miranda van Dongen, Linda J. W. Bosch, Mirthe Lanfermeijer, Samuel Angiuoli, Amy E. Greer, Ellen Verner, Jennifer B. Jackson, Rebecca A. Previs, Veerle M. H. Coupe, Daan van den Broek, Gerrit A. Meijer, Jill Phallen, Victor E. Velculescu, Anna J. S. van Tetering-Houben, Jeanine M. L. Roodhart, Niels F. M. Kok, Frederieke H. van der Baan, Mark Sausen, Miriam Koopman, Geraldine R. Vink, Remond J. A. Fijneman, the PLCRC-MEDOCC group
• CT158 Regorafenib plus avelumab in macrophage-low microsatellite-stable colorectal cancer: A prospective study Korakis Iphigenie, Sophie Cousin, Noemie Huchet, Jean-Philippe Metges, Philippe Cassier, Marc hilmi, Antoine Adenis, Antoine Hollebecque, Carine Bellera, Jean-Philippe Guegan, Alban Bessede, Antoine Italiano
• CT159 · PDF JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma in a randomized, multicenter, Phase II study Jian Zhou, Guoming Shi, Yongsheng Ge, Shuijun Zhang, Xiwen Huang, Shunda Du, Yong Gao, Guohong Han, Xiaoyong Huang, Zhenda Wang, Junliang Li, Jing Xu, Jiazheng Yan, Jianjun Zou, Jia Fan
• CT160 · PDF Updated multicenter phase Ib/II analysis of surufatinib plus sintilimab and capecitabine in previously treated metastatic small bowel adenocarcinoma and appendiceal carcinoma Xiaoyu Xie, Jianwei Zhang, Yue Cai, Xiaohui Lin, Huabin Hu, Jiayu Lin, Yan Zhang, Shanshan Li, Bohan Han, Yanhong Deng
• CT161 · PDF A phase II clinical trial of lurbinectedin in patients with advanced gastrointestinal malignancies with DNA repair mutations Alexa F. Viniotis, Gayle S. Jameson, Betsy C. Wertheim, Denise J. Roe, Daniel Mocan, Shelby Pearse, Sunil Sharma, Michael S. Gordon, Daniel D. Von Hoff, Erkut H. Borazanci
• CT162 · PDF Analysis of tumor and biomarker responses in the VIRAGE Trial, a randomized Phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC) Rocio Garcia-Carbonero, Roberto Pazo, Teresa Macarulla, Berta Laquente, Alana Nguyen, Carmen Guillén-Ponce, Andres J. Muñoz, Edward J. Kim, Mireya Cazorla, Tara Seery, Miriam Lobo de Mena, Chris Nevala-Plagemann, Vivek R. Sharma, Eva Martinez de Castro, Charles Le, Ana Mato-Berciano, Luis A. Rojas, Carmen Blasco, Manel Cascallo, Manuel Hidalgo
• CT163 · PDF Inhibiting fatty acid oxidation can overcome acquired drug resistance in pancreatic cancer: A Phase 2 trial has begun Soo-Youl Kim, Sang Woo, Wonyoung Choi, Joon Kang, Sung Sim, Jung Chun
• CT165 · PDF Modifying the tumor microenvironment in gastric and gastroesophageal junction adenocarcinoma using a cGMP-phosphodiesterase inhibitor Junaid Arshad, Lin Ding, Palash Mallick, Mohammad Khreiss, Aaron J. Scott, Rachna Shroff, Juanita Merchant
• CT166 · PDF A phase II study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in PD-1 refractory gastroesophageal cancer (GEC) Samuel L. Cytryn, Jeremy Tchack, Charlton Tsai, Yuval Elhanati, Patrick Evans, June Song, Michal Segal, Rory Mcgriskin, Amin Yaqubie, Joyce Lam, Haroon Kanishka, Michael B. Foote, Geoffrey Y. Ku, Steven B. Maron, Yelena Y. Janjigian

在完整检索应用中浏览本分会场 →